The use of a standardized nomenclature carries the danger of prematurely classifying substances that are not well characterized; this is to be avoided. On the other hand, it is exactly here where confusion and problems of terminology originate. The committee has therefore included guidelines for the naming of substances that are still hypothetical and which can be used only with the ending '-like' at present. Rule 4 of the general comments should be applied whenever possible.
Increasing knowledge will necessitate revision of the present nomenclature in the future. Suggestions for revisions may be sent to any member of the committee.
General Comments 1. Established trivial names will be retained.
2. The names of components are based on the zymogen or precursor form of the protein.
3. The amino acid sequence of components of the renal renin-angiotensin system of man is used as reference, and the numbering of peptides follows that of angiotensin I (1-10) decapeptide or renin substrate (1-14) tetradecapeptide.
4. The source (species, tissue) and the physicochemical characteristics (e.g., iso-electric point) must be specified in the initial description of each component. In the case of measurements of inactive forms of renin (or renin-like enzymes), the method of activation (e.g., acid-activation) and the molecular weight should be indicated (e.g., inactive renin; mol.wt. 60,000).
5. 'pro' should be used as a prefix; 'Pro' when a proline residue is implied.
6. The present nomenclature may require revision in the future. e.g. renin substrate-(7-13 )-heptapep tide 7 8 9 10 11 12 13 Pro-Phe-His-Leu-Leu-Val-Tyr [Pro-Pro]renin substrate-7 8 9 10 11 12 13 (7-13 )nonapeptide
Pro-Pro-Pro-Phe-His-Leu-Leu-Val-Tyr If larger peptides are synthesized, the terms, e.g. renin substrate-(7-l3 fragment or renin substrate-(l-35)fragment, may be used.
angiotensin-(l-lO) decapeptide
The term angiotensin ( 
